Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model

Journal of Investigative Dermatology

Volumn 127, Issue 10, 2007, Pages 2399-2410

  Mathieu, Véronique ^a   Le Mercier, Marie ^a   De Neve, Nancy ^b   Sauvage, Sébastien ^b   Gras, Thierry ^b   Roland, Isabelle ^b   Lefranc, Florence ^a,c   Kiss, Robert ^a,d  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Unibioscreen SA   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CATHEPSIN B; CISPLATIN; DOXORUBICIN; GALECTIN 1; HEAT SHOCK PROTEIN 70; IRINOTECAN; PACLITAXEL; SMALL INTERFERING RNA; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; HEAT SHOCK PROTEIN 72;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME MEMBRANE; MELANOMA; MEMBRANE PERMEABILITY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CATHEPSIN B; CELL LINE, TUMOR; CISPLATIN; DACARBAZINE; DISEASE MODELS, ANIMAL; FEMALE; GALECTIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP72 HEAT-SHOCK PROTEINS; MELANOMA; MICE; MICE, KNOCKOUT; RNA, SMALL INTERFERING; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34848896271     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700869     Document Type: Article

References (51)

1. Atallah E, Flaherty L (2005) Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6:185-93
2. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S et al. (2002) Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95:641-55
3. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H et al. (2002) Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61:585-96
4. Camby I, Le Mercier M, Lefranc F, Kiss R (2006) Galectin-1: a small protein with major functions. Glycobiology 16:137R-57R
5. 2: a potential small-molecule single-photon emission computed tomography probe for imaging metastatic melanoma. Cancer Res 65:4979-86
6. Danguy A, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285-93
7. Darro F, Decaestecker C, Gaussin JF, Mortier S, Van Ginckel R, Kiss R (2005) Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery? Int J Oncol 27:607-16
8. Debeir O, Van Ham P, Kiss R, Decaestecker C (2005) Tracking of migrating cells under phase-contrast video microscopy with combined mean-shift processes. IEEE Trans Med Imaging 24:697-711
9. Decaestecker C, Debeir O, Van Ham P, Kiss R (2007) Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 27:149-76
10. Del Bello B, Moretti D, Gamberucci A, Maellaro E (2006) Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. Oncogene [E-pub ahead of print]
11. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430:1034-9
12. Eskelinen EL (2006) Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Aspects Med 27:495-502
13. Fehrenbacher N, Jäättelä M (2005) Lysosomes as targets for cancer therapy. Cancer Res 65:2993-5
14. Glinsky GV, Glinsky VV (1996) Apoptosis and metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 101:43-51
15. He SJ, Stevens G, Braithwaite AW, Eccles MR (2005) Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther 4:996-1003
16. Hersey P (2006) Apoptosis and melanoma: how new insights are affecting the development of new therapies for melanoma. Curr Opin Oncol 18:189-96
17. Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, Darro F et al. (2006) Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 13:3513-27
18. Ivanov VN, Bhoumik A, Ronai Z (2003) Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152-61
19. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N et al. (2002) Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99:809-16
20. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448-57
21. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726-34
22. Kroemer G, Jäättelä M (2005) Lysosomes and autophagy in cell death control. Nat Rev Cancer 5:886-97
23. Kuwada SK, Kuang J, Li X (2005) Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells. J Biol Chem 280:19027-35
24. Lefranc F, Brotchi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23:2411-22
25. Lefranc F, Mijatovic T, Mathieu V, Rorive S, Decaestecker C, Debeir O et al. (2004) Characterization of gastrin-induced pro-angiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clin Cancer Res 10:8250-65
26. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R (2006) Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 6:719-32
27. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5:29-41
28. Maecker HL, Koumenis C, Giaccia AJ (2000) p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res 60:4638-44
29. Mathieu A, Saal I, Vuckovic A, Ransy V, Vereerstraten P, Kaltner H et al. (2005a) Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinomas and squamous cell carcinoma of the lung. Mod Pathol 18:1264-71
30. Mathieu V, Mijatovic T, Van Damme M, Kiss R (2005b) Gastrin exerts pleitropic effects on human melanoma cell biology. Neoplasia 7:930-43
31. Mijatovic T, Mathieu V, Gaussin JF, De Neve N, Ribaucour F, Van Quaquebeke E et al. (2006) Cardenolide-induced lysosomal membrane permeabilization contributes therapeutic benefits in experimental human non-small-cell-lung cancers. Neoplasia 8:402-12
32. Miller AJ, Mihm MC Jr (2006) Melanoma mechanisms of disease. N Engl J Med 355:51-65
33. Na KY, Woo SK, Lee SD, Kwon HM (2003) Silencing of TonEBP/NFAT5 transcriptional activator by RNA interference. J Am Soc Nephrol 14:283-8
34. Nylandsted J, Gyrd-Hansen M, Danielewicz A, Fehrenbacher N, Lademann U, Hoyer-Hansen M et al. (2004) Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 200:425-35
35. Ozawa K, Tsukamoto Y, Hori O, Kitao Y, Yanagi H, Stern DM et al. (2001) Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmic reticulum chaperone. Cancer Res 61:4206-13
36. Pattingre S, Levine B (2006) Bcl-2 inhibition of autophagy: a new route to cancer? Cancer Res 66:2885-8
37. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y (2001) Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20:7486-93
38. Perillo NL, Pace KE, Seilhamer JJ, Baum LG (1995) Apoptosis of T cells mediated by galectin-1. Nature 378:736-9
39. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF et al. (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O(6)-methylguanine. Oncogene 26:186-97
40. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A et al. (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 5:241-51
41. Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A et al. (2006) Heat shock protein 70 neutralization exerts potent anti-tumor effects in animal models of colon cancer and melanoma. Cancer Res 66:4191-7
42. Schmitt E, Parcellier A, Gurbuxani S, Cande C, Hammann A, Morales MC et al. (2003) Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res 63:8233-40
43. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44
44. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT et al. (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoproteins receptors to induce T cell death. J Immunol 176:778-89
45. Stillman BN, Mischel PS, Baum LG (2005) New roles for galectins in brain tumors - from prognostic markers to therapeutic targets. Brain Pathol 15:124-32
46. Tas F, Argon A, Camlica H, Topuz E (2005) Temozolomide in combination with cisplatin in patients with metastatic melanoma: a Phase II trial. Melanoma Res 15:543-8
47. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S et al. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975-80
48. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT (2001) Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 91:167-72
49. Toker A, Yoeli-Lerner M (2006) Akt signalling and cancer: surviving but not moving on. Cancer Res 66:3963-6
50. Walzel H, Blach M, Hirabayashi J, Arata Y, Kasai KI, Brock J (2002) Galectin-induced activation of the transcription factors NFAT and AP-1 in human Jurkat T-lymphocytes. Cell Signal 14:861-8
51. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J (2006) Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168:1666-75